Funding for this research was provided by:
Key Technologies Research and Development Program (2018YFC1705700)
Received: 18 December 2019
Accepted: 8 May 2020
First Online: 5 June 2020
Ethics approval and consent to participate
: The protocol has been approved by the Medical Ethics Committee of Hangzhou Xixi Hospital, China (for central ethical approval), and the other centers in the trial will not begin recruiting until local ethical approval has been obtained. All study participants will sign two informed consent forms, one kept by the patients and the other kept by the researcher. The results of this study will be published in a peer-reviewed journal.
: According to the terms of the informed consent, unless the subject’s consent is obtained, all the subject’s personal information is confidential and will not be disclosed to the public. When it is necessary, the drug supervision and administration department, ethics committee, or project funding department may consult the subject’s data. Without permission, they will not use the subject’s information for other purposes or disclose it to other groups.
: The authors declare that they have no competing interests.